Atea Pharmaceuticals, Inc.
AVIR
Rank in Stocks
#13950
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company,... Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Share Price
$4.41
Last synced: 2026-11-09
Market Cap
$353.70M
Change (1 day)
2.32%
Change (1 year)
30.47%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Atea Pharmaceuticals, Inc. (AVIR)
Category
Healthcare
Operating Margin for Atea Pharmaceuticals, Inc. (AVIR)
Operating Margin as of November 2026 TTM: 0.00%
According to Atea Pharmaceuticals, Inc.'s latest financial reports, its current operating margin (TTM) is 0.00%. At the end of 2025 the company had an operating margin of 0.00%.
Operating Margin history for Atea Pharmaceuticals, Inc. from 2018 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 0.00% | 0.00% |
| 2025 | 0.00% | 0.00% |
| 2024 | 0.00% | 0.00% |
| 2023 | 0.00% | 0.00% |
| 2022 | 0.00% | -100.00% |
| 2021 | 39.38% | -273.63% |
| 2020 | -22.68% | 0.00% |
| 2019 | 0.00% | 0.00% |
| 2018 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | - |
US
|
|
| -149.01% | - |
US
|
|
| 25.57% | - |
AU
|
|
| 31.23% | - |
BE
|
|
| 29.35% | - |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Atea Pharmaceuticals, Inc.'s operating margin
What was Atea Pharmaceuticals, Inc.'s operating margin in 2025?
In 2025, Atea Pharmaceuticals, Inc.'s operating margin was 0.00%, compared with 0.00% in 2024.
How has Atea Pharmaceuticals, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Atea Pharmaceuticals, Inc.'s operating margin was highest in 2021 (39.38%) and lowest in 2020 (-22.68%).
How does Atea Pharmaceuticals, Inc.'s operating margin compare with similar companies?
Atea Pharmaceuticals, Inc.'s operating margin (0.00%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.